CEL-SCI Reports April 2014 Is Another Record Month For Patient Enrollment In Its Phase 3 Head And Neck Cancer Trial

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the month of April 2014 the Company enrolled 21 patients with advanced primary, not yet treated, head and neck cancer into its global Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). This marks a substantial increase over the previous monthly record of 14 patients in March 2014.

Help employers find you! Check out all the jobs and post your resume.